0.0122USD-11.59%Mkt Cap: —P/E: —2d ago
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.80M $
Revenue/Share—
Last Price0.0122 USD
Fiscal Year End—
MR Quarter—
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.10
EPS (TTM)-3.84
EPS (Forward)—
52W Range
0.006740% of range0.0204
52W High0.0204 USD
52W Low0.0067 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1826.09%
ROA-211.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.16M $
CapEx (TTM)7.00K $
FCF Margin—
FCF Yield—
Net Debt-13.39M $
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity0.30
Current Ratio2.26
Quick Ratio1.57
Book Value/Sh0.1210 USD
Cash/Share0.5050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float23.31M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta3.03
S&P 52W Chg18.16%
Avg Vol (30d)8.05K
Avg Vol (10d)—
Technical Indicators
RSI (14)32.1
MACD-0.0020
MACD Signal-0.0016
MACD Hist.-0.0004
BB Upper0.0249 USD
BB Middle0.0170 USD
BB Lower0.0091 USD
BB Width93.10%
ATR (14)0.0019 USD
Vol Ratio (20d)0.79x